Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on Immunovant from 11 firms (1 sell, 4 hold, 6 buy), with an average 1‑year price target of about $32.44.
• Company insiders have been selling recently to cover tax withholding on vested awards — the CTO and CFO sold shares (total insiders sold 72,141 shares worth ~$1.92M in the last 90 days), leaving insiders with about 1.80% ownership.
• Immunovant trades around $27.12 with a market cap of ~$5.52B, a 52‑week range of $13.36–$30.09 and a negative P/E (-10.08); the company reported a recent quarterly EPS of -$0.61 (beating estimates) and analysts expect about -2.67 EPS for the year.

Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eleven research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $32.4444.

Several research analysts recently issued reports on IMVT shares. Truist Financial increased their target price on shares of Immunovant from $16.00 to $22.00 and gave the stock a "hold" rating in a research note on Thursday, January 8th. Guggenheim increased their target price on shares of Immunovant from $41.00 to $44.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of Immunovant in a research note on Wednesday, April 8th. Sanford C. Bernstein started coverage on shares of Immunovant in a research note on Friday, March 20th. They set a "market perform" rating and a $28.00 target price on the stock. Finally, Wolfe Research raised shares of Immunovant from a "peer perform" rating to an "outperform" rating and set a $50.00 target price on the stock in a research note on Tuesday, January 6th.

Insider Buying and Selling at Immunovant

In other Immunovant news, CTO Jay S. Stout sold 10,132 shares of the firm's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $24.83, for a total value of $251,577.56. Following the transaction, the chief technology officer directly owned 254,439 shares of the company's stock, valued at approximately $6,317,720.37. This trade represents a 3.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Tiago Girao sold 25,760 shares of the firm's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $29.62, for a total transaction of $763,011.20. Following the completion of the transaction, the chief financial officer directly owned 247,596 shares in the company, valued at $7,333,793.52. This trade represents a 9.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 72,141 shares of company stock valued at $1,923,713 over the last 90 days. Insiders own 1.80% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IMVT. Geneos Wealth Management Inc. bought a new position in shares of Immunovant in the fourth quarter valued at $25,000. Strs Ohio bought a new position in shares of Immunovant in the first quarter valued at $27,000. Aster Capital Management DIFC Ltd bought a new position in shares of Immunovant in the third quarter valued at $33,000. PNC Financial Services Group Inc. lifted its stake in shares of Immunovant by 138.9% in the third quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company's stock valued at $46,000 after buying an additional 1,646 shares in the last quarter. Finally, Quarry LP lifted its stake in shares of Immunovant by 94.9% in the fourth quarter. Quarry LP now owns 3,000 shares of the company's stock valued at $76,000 after buying an additional 1,461 shares in the last quarter. 47.08% of the stock is owned by institutional investors.

Immunovant Stock Performance

NASDAQ:IMVT opened at $27.12 on Friday. The firm's fifty day moving average is $26.09 and its 200-day moving average is $24.98. Immunovant has a 52 week low of $13.36 and a 52 week high of $30.09. The firm has a market cap of $5.52 billion, a P/E ratio of -10.08 and a beta of 0.70.

Immunovant (NASDAQ:IMVT - Get Free Report) last issued its earnings results on Friday, February 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.11. During the same quarter in the prior year, the business earned ($0.76) EPS. As a group, sell-side analysts anticipate that Immunovant will post -2.67 earnings per share for the current year.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant's approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company's lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.